Structure-activity relationships and pharmacological profiles of new 5-HT, receptor agonists as antimigraine agents

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 4, 1999, Pages 304-310

  Ferez, Michel ^a   John, Gareth W ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (3 FLUOROPHENYL)ETHYL] 4 [3 [5 (1,2,4 TRIAZOL 4 YL) 1H INDOL 3 YL]PROPYL]PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 4 [4 [2 [3 (2 AMINOETHYL) 1H INDOL 5 YLOXY]ACETYL]PIPERAZIN 1 YL]BENZONITRILE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ISOCHROMAN DERIVATIVE; NARATRIPTAN; PYRROLIDINE DERIVATIVE; SEROTONIN 1D AGONIST; SUMATRIPTAN; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; HEADACHE; MIGRAINE; RECEPTOR SENSITIVITY; STRUCTURE ACTIVITY RELATION;

EID: 0032780399     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Goldstein ME, Chen TC.The epidemiology of disabling headache. Adv Neural (1982) 33:377-390.
2. Feniuk W, Humphrey PP.The development of a highly selective 5-HT, receptor agonist, sumatriptan for the treatment of migraine. Drug Dev Res (1992) 26:235-240.
3. Ferrari MD.Migraine. tance/(1998) 351:1043-1051.
4. •• A succinct review and analysis of the current acute treatments of migraine on the market.
5. Pauwels PJ, John GW.Review.Present and future on 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol (1999) 22(3):123-136.
6. Goadsby PJ.Serotonin 5-HT1lv,D receptor agonists in migraine. Comparative pharmacology and its therapeutic implications. CNS Drugs (1998) 10(4):271-286.
7. •• Very complete analysis on the possible mechanisms of action of the triptans.
8. Johnson KW, Schaus JM, Cohen ML, Audia JE, Kaldor SW. Flaugh ME, Krushinski JH, Schenck KW, Kiefer AD, Nissen JS, Dressman BA, Zgombick JM, Branchek TA, Adham N, Phebus LA.Inhibition of neurogenic protein extravasation in the dura via 5-HT1F receptor activation - implications to migraine therapy. Soc Neurosci (1996) 22(528.10):13301330.
9. MacLeod AM, Street LJ, Reeve AJ, Jelley RA, Stemfeld F, Beer MS, Stanton JA, Watt AP, Rathbone D, Matassa VG.Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Mod Chem (1997) 40(22):3501-3503.
10. Castro JL, Collins I, Russell MG, Watt AP, Sohal B, Rathbone D, Beer MS, Stanton JA.Enhancement of oral absorption in selective 5-HT1D receptor agonists.fluorinated 3-[3(piperidin-1-yl)propyl]indoles. J Med Chem (1998) 41(15):2667-2670.
11. Stemfeld F, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Hunt PA, Beer MS, Heald A, Stanton JA, Sohal B, Watt AP, Street LJ.Synthesis and serotonergic activity of 3-[2(pyrrolidin-1-yl)ethyl]indoles.potent agonists for the h5HT10 receptor with high selectivity over the h5-HTIB receptor. J Med Chem (1999) 42:677-690.
12. Chambers MS, Street LJ, Goodacre S, Hobbs SC, Hunt P, Jelley RA, Matassa VG, Reeve AJ, Stemfeld F. Beer MS, Stanton JA, Rathbone D, Watt AP, MacLeod AM.3(Piperazinylpropyl)indoles.selective, orally bioavailable h5-HT10 receptor agonists as potential antimigraine agents. J Med Chem (1999) 42:691-705.
13. • Interesting observations concerning the 5-HT,0 receptor binding site.
14. Ennis MD, Ghazal NB, Huffman RL, Smith MW, Schlachter SK, Lawson CF, Im WB, Pregenzer JF, Svensson KA, Lewis RA, Hall ED, Sutter DM, Ham's LT, McCall RB.lsochroman-6carboxamides as highly selective 5-HT1D agonists.potential new treatment for migraine without cardiovascular side effects. J Med Chem (1998) 41:21 BO2183.
15. •• The most selective 5-HT,D receptor agonist described to date.
16. Bondarev M, IwamuraT, Hynd D, Mazzocco L, Lee DK, Dukat M, Glennon RA.Aryloxyethylamines as h5-HTln serotonin receptor ligands. Med Chem Res (1998) 8:333-342.
17. Law H, Dukat M, Teitler M, Lee DK, Mazzocco L, Kamboj R, Rampersard V, Prisinzano T, Glennon RA.Benzylimidazolines as h5-HT,WD serotonin receptor ligands.a structure-affinity investigation. J Med Chem (1998; 41:2243-2251.
18. Xu YC, Schaus JM, Walker C, Krushinski J, Adham N, Zgombick JM, Liang SX, Kohlman DT, Audia JE.W-methyl-5terf-butyltryptamine.A novel, highly potent 5-HT,D receptor agonist J Med Chem (1999) 42:526-531.
19. Glennon RA, Hong S3, Bondarev M, Law H, Dukat M, Rakhi S, Power P, Fan E, Kinneau D, Kamboj R, Teitler M, HerrickDavis K, Smith C.Binding of O-alkyl derivatives of serotonin at human 5-HT1 D receptors. J Med Chem (1996) 39:314-322.
20. Barf T, Wikström H, Pauwels PJ, Palmier C, Tardif S, Lundmark M, Sundell S.5-(Sulfonyl)oxy-tryptamines and ethylamino side chain restricted derivatives. Structureaffinity relationships for h5-HT,a and h5-HT1D receptors. Bioorg Med Chem (1998) 6:1469-1479.
21. Perez M, Pallard I, Fourrier C, Potier P, Pauwels PJ. Palmier C, Valentin JP, John GW, Halazy S.SAR studies on close analogs of F-11356.a novel series of highly efficacious and selective h 5-HTlara receptor agonists for the acute treatment of migraine. 276" ACS Meeting Boston, USA (1998):MED1142.
22. John GW, Pauwels PJ, Perez M, Halazy S. Le Grand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P, Marien M, Kleven MS, Koek W, Assié MB, Carilla-Durand E, Tarayre JP, Colpaert FC.F 11356, a novel 5-HT derivative with potent, selective and unique high intrinsic activity at 5-HT]Bno receptors in models relevant to migraine. J Pharmacol Exp T/jer(1999) in press.
23. Perez M, Jorand-Lebrun C, Pauwels PJ, Pallard I, Halazy S.Dimers of 5HT, ligands preferentially bind to 5HTiano receptor subtypes. Bioorg Med Chem Lett (1998) 8:14071412.